

A Closer Look at Three Biotech Cases Dealing with the Timing Issue

- Amgen v. Hoechst and TKT (Fed. Cir. 2003)
 - Amgen holder of several patents directed to production of EPO
 - TKT used homologous recombination to insert viral promoter elements into chromosomal DNA to activate expression of endogenous EPO

protect
ideas
increase
value